Hudson Capital Management LLC Buys 761 Shares of Humana Inc (HUM)

Share on StockTwits

Hudson Capital Management LLC lifted its stake in Humana Inc (NYSE:HUM) by 20.6% during the 1st quarter, Holdings Channel reports. The firm owned 4,460 shares of the insurance provider’s stock after acquiring an additional 761 shares during the period. Hudson Capital Management LLC’s holdings in Humana were worth $1,186,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc raised its stake in shares of Humana by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after purchasing an additional 140,864 shares during the period. Janus Henderson Group PLC raised its stake in shares of Humana by 3.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,596,204 shares of the insurance provider’s stock valued at $956,594,000 after purchasing an additional 120,905 shares during the period. Geode Capital Management LLC raised its stake in shares of Humana by 8.3% in the 4th quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock valued at $507,198,000 after purchasing an additional 135,776 shares during the period. Northern Trust Corp raised its stake in shares of Humana by 4.2% in the 4th quarter. Northern Trust Corp now owns 1,735,298 shares of the insurance provider’s stock valued at $497,128,000 after purchasing an additional 70,079 shares during the period. Finally, Norges Bank acquired a new stake in shares of Humana in the 4th quarter valued at about $402,117,000. Institutional investors and hedge funds own 90.27% of the company’s stock.

In related news, insider Christopher H. Hunter sold 15,586 shares of Humana stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $305.24, for a total transaction of $4,757,470.64. Following the completion of the transaction, the insider now owns 28,100 shares in the company, valued at $8,577,244. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.54% of the company’s stock.

Humana stock opened at $263.33 on Friday. Humana Inc has a 52 week low of $225.65 and a 52 week high of $355.88. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65. The stock has a market cap of $34.67 billion, a P/E ratio of 18.10, a price-to-earnings-growth ratio of 1.05 and a beta of 0.88.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, topping analysts’ consensus estimates of $4.30 by $0.18. Humana had a return on equity of 20.77% and a net margin of 2.99%. The business had revenue of $16.11 billion during the quarter, compared to analysts’ expectations of $15.67 billion. During the same quarter last year, the company posted $3.36 earnings per share. Humana’s quarterly revenue was up 12.8% on a year-over-year basis. As a group, sell-side analysts predict that Humana Inc will post 17.57 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s payout ratio is currently 15.12%.

HUM has been the topic of several recent research reports. Credit Suisse Group dropped their price target on Humana from $352.00 to $315.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. Citigroup lowered their target price on Humana from $397.00 to $362.00 and set a “buy” rating on the stock in a research report on Thursday, February 7th. Barclays lowered their target price on Humana from $351.00 to $327.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 17th. Oppenheimer lowered their target price on Humana from $373.00 to $350.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Finally, ValuEngine downgraded Humana from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $337.26.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/4353338/hudson-capital-management-llc-buys-761-shares-of-humana-inc-hum.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also: Risk Tolerance

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report